Molecular markers in thyroid cancer diagnostics.

[1]  Y. Jo,et al.  Diagnostic value of pyrosequencing for the BRAFV600E mutation in ultrasound‐guided fine‐needle aspiration biopsy samples of thyroid incidentalomas , 2009, Clinical endocrinology.

[2]  N. Mitsiades,et al.  Molecular pathology of thyroid cancer: diagnostic and clinical implications. , 2008, Best practice & research. Clinical endocrinology & metabolism.

[3]  A. Miyauchi,et al.  Cytoplasmic and serum galectin-3 in diagnosis of thyroid malignancies. , 2008, Biochemical and biophysical research communications.

[4]  J. Eshleman,et al.  Differentiating alternative splice variant patterns of human telomerase reverse transcriptase in thyroid neoplasms. , 2008, Thyroid : official journal of the American Thyroid Association.

[5]  K. Arihiro,et al.  RET/PTC rearrangements preferentially occurred in papillary thyroid cancer among atomic bomb survivors exposed to high radiation dose. , 2008, Cancer research.

[6]  Q. Duh,et al.  Does the 3‐gene diagnostic assay accurately distinguish benign from malignant thyroid neoplasms? , 2008, Cancer.

[7]  M. Nga,et al.  HBME‐1 and CK19 are highly discriminatory in the cytological diagnosis of papillary thyroid carcinoma , 2008, Diagnostic cytopathology.

[8]  F. Pattou,et al.  Serum galectin-1 and galectin-3 levels in benign and malignant nodular thyroid disease. , 2008, Thyroid : official journal of the American Thyroid Association.

[9]  Steven J. M. Jones,et al.  Molecular Phenotyping of Thyroid Tumors Identifies a Marker Panel for Differentiated Thyroid Cancer Diagnosis , 2008, Annals of Surgical Oncology.

[10]  T. Fahey,et al.  MicroRNA analysis as a potential diagnostic tool for papillary thyroid carcinoma , 2008, Modern Pathology.

[11]  S. Libutti,et al.  Identification of Genes Differentially Expressed in Benign versus Malignant Thyroid Tumors , 2008, Clinical Cancer Research.

[12]  M. P. Martegani,et al.  Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study. , 2008, The Lancet. Oncology.

[13]  W. Kim,et al.  Pyrosequencing Analysis for Detection of a BRAFV600E Mutation in an FNAB Specimen of Thyroid Nodules , 2008, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[14]  G. Tseng,et al.  MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. , 2008, The Journal of clinical endocrinology and metabolism.

[15]  Yuri E Nikiforov,et al.  Thyroid carcinoma: molecular pathways and therapeutic targets , 2008, Modern Pathology.

[16]  R. Houlgatte,et al.  Microarray analysis refines classification of non-medullary thyroid tumours of uncertain malignancy , 2008, Oncogene.

[17]  Nitin A. Pagedar,et al.  Molecular Classification of Thyroid Nodules by Cytology , 2008, The Laryngoscope.

[18]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[19]  F. Sebag,et al.  Utility of malignancy markers in fine-needle aspiration cytology of thyroid nodules: comparison of Hector Battifora mesothelial antigen-1, thyroid peroxidase and dipeptidyl aminopeptidase IV , 2008, British Journal of Cancer.

[20]  M. Latteri,et al.  Fine-needle aspiration molecular analysis for the diagnosis of papillary thyroid carcinoma through BRAF V600E mutation and RET/PTC rearrangement. , 2007, Thyroid : official journal of the American Thyroid Association.

[21]  C. Croce,et al.  Specific microRNAs are downregulated in human thyroid anaplastic carcinomas , 2007, Oncogene.

[22]  A. Carvalho,et al.  Is galectin-3 a good method for the detection of malignancy in patients with thyroid nodules and a cytologic diagnosis of "follicular neoplasm"? A critical appraisal of the evidence. , 2007, Head & neck.

[23]  Jack Yang,et al.  Fine‐needle aspiration of thyroid nodules: A study of 4703 patients with histologic and clinical correlations , 2007, Cancer.

[24]  O. Sheils,et al.  A molecular expression signature distinguishing follicular lesions in thyroid carcinoma using preamplification RT-PCR in archival samples , 2007, Modern Pathology.

[25]  C. Croce,et al.  MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. , 2007, Endocrine-related cancer.

[26]  Krzysztof Fujarewicz,et al.  A multi-gene approach to differentiate papillary thyroid carcinoma from benign lesions: gene selection using support vector machines with bootstrapping , 2007, Endocrine-related cancer.

[27]  C. Larsson,et al.  A PCR-based expression signature of malignancy in follicular thyroid tumors. , 2007, Endocrine-related cancer.

[28]  G. Troncone,et al.  Detection of RET/PTC, TRK and BRAF mutations in preoperative diagnosis of thyroid nodules with indeterminate cytological findings , 2007, Clinical endocrinology.

[29]  Yao-Tseng Chen,et al.  Diagnostic usefulness of HBME1, galectin-3, CK19, and CITED1 and evaluation of their expression in encapsulated lesions with questionable features of papillary thyroid carcinoma. , 2006, American journal of clinical pathology.

[30]  B. Cho,et al.  Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto‐pathology diagnosis, especially in BRAFV600E mutation‐prevalent area , 2006, Clinical endocrinology.

[31]  Tae Yong Kim,et al.  The BRAF mutation is useful for prediction of clinical recurrence in low‐risk patients with conventional papillary thyroid carcinoma , 2006, Clinical endocrinology.

[32]  C. Eng,et al.  A limited set of human MicroRNA is deregulated in follicular thyroid carcinoma. , 2006, The Journal of clinical endocrinology and metabolism.

[33]  X. Qian,et al.  BRAF Mutation Analysis in Fine Needle Aspiration (FNA) Cytology of the Thyroid , 2006, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[34]  T. Fahey,et al.  Microarray analysis of thyroid nodule fine-needle aspirates accurately classifies benign and malignant lesions. , 2006, The Journal of molecular diagnostics : JMD.

[35]  J. Burdman,et al.  Telomerase activity in fine needle aspiration biopsy samples: application to diagnosis of human thyroid carcinoma. , 2006, Clinica chimica acta; international journal of clinical chemistry.

[36]  E. Kebebew,et al.  Diagnostic and extent of disease multigene assay for malignant thyroid neoplasms , 2006, Cancer.

[37]  C. Lombardi,et al.  Simultaneous immunohistochemical expression of HBME‐1 and galectin‐3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid , 2006, Histopathology.

[38]  Louise Davies,et al.  Increasing incidence of thyroid cancer in the United States, 1973-2002. , 2006, JAMA.

[39]  L. Rowe,et al.  Utility of BRAF V600E mutation detection in cytologically indeterminate thyroid nodules , 2006, CytoJournal.

[40]  David E. Misek,et al.  Delineation, Functional Validation, and Bioinformatic Evaluation of Gene Expression in Thyroid Follicular Carcinomas with the PAX8-PPARG Translocation , 2006, Clinical Cancer Research.

[41]  Q. Duh,et al.  Diagnostic and Prognostic Value of Cell-cycle Regulatory Genes in Malignant Thyroid Neoplasms , 2006, World Journal of Surgery.

[42]  N. Asaad,et al.  Human telomerase reverse transcriptase (hTERT) gene expression in thyroid carcinoma: diagnostic and prognostic role. , 2006, Journal of the Egyptian National Cancer Institute.

[43]  Mi-Jung Kim,et al.  Diagnostic Utility of Galectin-3 in Aspirates of Thyroid Follicular Lesions , 2006, Acta Cytologica.

[44]  T. Giordano,et al.  Correlation Between Genetic Alterations and Microscopic Features, Clinical Manifestations, and Prognostic Characteristics of Thyroid Papillary Carcinomas , 2006, The American journal of surgical pathology.

[45]  A. Bartolazzi,et al.  Galectin‐3 does not reliably distinguish benign from malignant thyroid neoplasms , 2006, Histopathology.

[46]  E. Lerma,et al.  Telomerase activity in “suspicious” thyroid cytology , 2005, Cancer.

[47]  S. Libutti,et al.  A six-gene model for differentiating benign from malignant thyroid tumors on the basis of gene expression. , 2005, Surgery.

[48]  Q. Duh,et al.  Diagnostic and prognostic value of angiogenesis-modulating genes in malignant thyroid neoplasms. , 2005, Surgery.

[49]  T. Fahey,et al.  Molecular analysis of minimally invasive follicular carcinomas by gene profiling. , 2005, Surgery.

[50]  P. Ladenson,et al.  BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. , 2005, The Journal of clinical endocrinology and metabolism.

[51]  J. Collet,et al.  Galectin-3 immunodetection in follicular thyroid neoplasms: a prospective study on fine-needle aspiration samples , 2005, British Journal of Cancer.

[52]  Q. Duh,et al.  ECM1 and TMPRSS4 Are Diagnostic Markers of Malignant Thyroid Neoplasms and Improve the Accuracy of Fine Needle Aspiration Biopsy , 2005, Annals of surgery.

[53]  S. Pambuccian,et al.  Interobserver variability in thyroid fine-needle aspiration interpretation of lesions showing predominantly colloid and follicular groups. , 2005, American journal of clinical pathology.

[54]  T. Fahey,et al.  Advancing the molecular diagnosis of thyroid nodules: defining benign lesions by molecular profiling. , 2005, Thyroid : official journal of the American Thyroid Association.

[55]  S. Michiels,et al.  Tumorigenesis and Neoplastic Progression Follicular Thyroid Tumors with the PAX 8-PPAR 1 Rearrangement Display Characteristic Genetic Alterations , 2005 .

[56]  M. Papotti,et al.  Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application. , 2005, Endocrine-related cancer.

[57]  Lei Zhang,et al.  Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. , 2005, Cancer research.

[58]  C. Lombardi,et al.  Immunocytochemical evaluation of thyroid neoplasms on thin‐layer smears from fine‐needle aspiration biopsies , 2005, Cancer.

[59]  T. Dwight,et al.  Expression profiling reveals a distinct transcription signature in follicular thyroid carcinomas with a PAX8-PPARγ fusion oncogene , 2005, Oncogene.

[60]  Krzysztof Fujarewicz,et al.  Gene expression profile of papillary thyroid cancer: sources of variability and diagnostic implications. , 2005, Cancer research.

[61]  R. Domingues,et al.  Searching for RET/PTC rearrangements and BRAF V599E mutation in thyroid aspirates might contribute to establish a preoperative diagnosis of papillary thyroid carcinoma , 2005, Cytopathology : official journal of the British Society for Clinical Cytology.

[62]  T. Fahey,et al.  Molecular analysis of Hurthle cell neoplasms by gene profiling. , 2004, Surgery.

[63]  Y. Nikiforov,et al.  Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. , 2004, The Journal of clinical endocrinology and metabolism.

[64]  S. Liyanarachchi,et al.  Papillary and follicular thyroid carcinomas show distinctly different microarray expression profiles and can be distinguished by a minimum of five genes. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  C. Barden,et al.  Discrimination of Benign and Malignant Thyroid Nodules by Molecular Profiling , 2004, Annals of surgery.

[66]  P. Beck‐Peccoz,et al.  BRAF mutations in an Italian cohort of thyroid cancers , 2004, Clinical endocrinology.

[67]  L. Sobrinho,et al.  Underexpression of peroxisome proliferator-activated receptor (PPAR)γ in PAX8/PPARγ-negative thyroid tumours , 2004, British Journal of Cancer.

[68]  E. Lerma,et al.  Telomerase Activity in Thyroid Fine Needle Aspirates , 2004, Acta Cytologica.

[69]  T. Fahey,et al.  0021-972X/04/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 89(7):3214–3223 Printed in U.S.A. Copyright © 2004 by The Endocrine Society doi: 10.1210/jc.2003-031811 Molecular Profiling Distinguishes Papillary Carcinoma , 2022 .

[70]  P. Ladenson,et al.  Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. , 2004, The Journal of clinical endocrinology and metabolism.

[71]  T. Nagaya,et al.  Is thyroid follicular cancer in Japanese caused by a specific t(2; 3)(q13; p25) translocation generating Pax8-PPAR gamma fusion mRNA? , 2004, Endocrine journal.

[72]  N. Eberhardt,et al.  The PAX8/PPARγ fusion oncoprotein transforms immortalized human thyrocytes through a mechanism probably involving wild-type PPARγ inhibition , 2004, Oncogene.

[73]  S. Libutti,et al.  Using gene expression profiling to differentiate benign versus malignant thyroid tumors. , 2004, Cancer research.

[74]  Jennifer Shoemaker,et al.  A preoperative diagnostic test that distinguishes benign from malignant thyroid carcinoma based on gene expression. , 2004, The Journal of clinical investigation.

[75]  D. Clark,et al.  Mutational Analysis of BRAF in Fine Needle Aspiration Biopsies of the Thyroid: A Potential Application for the Preoperative Assessment of Thyroid Nodules , 2004, Clinical Cancer Research.

[76]  W. Kolch,et al.  Oncogenic B-Raf mutations: crystal clear at last. , 2004, Cancer cell.

[77]  G. Tsujimoto,et al.  Gene Expression Profiling Identifies Platelet-Derived Growth Factor as a Diagnostic Molecular Marker for Papillary Thyroid Carcinoma , 2004, Clinical Cancer Research.

[78]  M. Nikiforova,et al.  BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. , 2003, The Journal of clinical endocrinology and metabolism.

[79]  T. Dwight,et al.  Involvement of the PAX8/peroxisome proliferator-activated receptor gamma rearrangement in follicular thyroid tumors. , 2003, The Journal of clinical endocrinology and metabolism.

[80]  G. Fontanini,et al.  Galectin-3 and oncofetal-fibronectin expression in thyroid neoplasia as assessed by reverse transcription-polymerase chain reaction and immunochemistry in cytologic and pathologic specimens. , 2003, Thyroid : official journal of the American Thyroid Association.

[81]  P. Söderkvist,et al.  Telomerase activity in surgical specimens and fine-needle aspiration biopsies from hyperplastic and neoplastic human thyroid tissues. , 2003, American journal of surgery.

[82]  C. Barden,et al.  Classification of follicular thyroid tumors by molecular signature: results of gene profiling. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[83]  M. Kaminishi,et al.  Clinical application of human telomerase reverse transcriptase gene expression in thyroid follicular tumors by fine-needle aspirations using in situ hybridization. , 2003, International journal of oncology.

[84]  Yuri E Nikiforov,et al.  RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. , 2003, The Journal of clinical endocrinology and metabolism.

[85]  Grace C H Yang,et al.  Should cytopathologists stop reporting follicular neoplasms on fine‐needle aspiration of the thyroid? , 2003, Cancer.

[86]  P. Ladenson,et al.  BRAF mutation in papillary thyroid carcinoma. , 2003, Journal of the National Cancer Institute.

[87]  Yuri E Nikiforov,et al.  High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. , 2003, Cancer research.

[88]  竹中 幸則.  Malignant transformation of thyroid follicular cells by galectin-3 , 2003 .

[89]  Jen-Der Lin,et al.  Human telomerase reverse transcriptase (hTERT) gene expression in FNA samples from thyroid neoplasms. , 2003, Cancer letters.

[90]  M. Nikiforova,et al.  PAX8-PPAR&ggr; Rearrangement in Thyroid Tumors: RT-PCR and Immunohistochemical Analyses , 2002, The American journal of surgical pathology.

[91]  C. Poremba,et al.  Expression of telomerase genes in thyroid carcinoma. , 2002, International journal of oncology.

[92]  L. Sobrinho,et al.  Expression of PAX8-PPARγ1 Rearrangements in Both Follicular Thyroid Carcinomas and Adenomas , 2002 .

[93]  G. Francis,et al.  Thyroid carcinomas that express telomerase follow a more aggressive clinical course in children and adolescents , 2002, Journal of endocrinological investigation.

[94]  Z. Baloch,et al.  Diagnosis of “follicular neoplasm”: A gray zone in thyroid fine‐needle aspiration cytology , 2002, Diagnostic cytopathology.

[95]  K. Mokbel,et al.  The significance of human telomerase reverse transcriptase (hTERT) in cancer. , 2001, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[96]  C. Peyssonnaux,et al.  The Raf/MEK/ERK pathway: new concepts of activation , 2001, Biology of the cell.

[97]  A. Pinchera,et al.  RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults. , 2001, The Journal of clinical endocrinology and metabolism.

[98]  Christopher J. Jones,et al.  Telomerase activity and telomere length in thyroid neoplasia: biological and clinical implications , 2001, The Journal of pathology.

[99]  G. Yang,et al.  Ultrasound-guided fine-needle aspiration of the thyroid assessed by Ultrafast Papanicolaou stain: data from 1135 biopsies with a two- to six-year follow-up. , 2001, Thyroid : official journal of the American Thyroid Association.

[100]  C. Cheung,et al.  Analysis of ret/PTC gene rearrangements refines the fine needle aspiration diagnosis of thyroid cancer. , 2001, The Journal of clinical endocrinology and metabolism.

[101]  K. Azarow,et al.  Does telomerase activity add to the value of fine needle aspirations in evaluating thyroid nodules? , 2001, American journal of surgery.

[102]  T. Yoshii,et al.  Galectin-3 maintains the transformed phenotype of thyroid papillary carcinoma cells. , 2001, International journal of oncology.

[103]  S. Groshen,et al.  Follicular lesions of thyroid , 2000, Cancer.

[104]  M. Kaminishi,et al.  Telomerase activity and telomere length in benign and malignant human thyroid tissues. , 2000, Cancer letters.

[105]  C. J. Chen,et al.  PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. , 2000, Science.

[106]  B. Spiegelman,et al.  PAX8-PPARγ1 Fusion in Oncogene Human Thyroid Carcinoma , 2000 .

[107]  J. Luk,et al.  Telomerase activity in thyroid malignancy. , 1999, Thyroid : official journal of the American Thyroid Association.

[108]  T. Yoshii,et al.  Expression of galectin‐3 in fine‐needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms , 1999, Cancer.

[109]  S. Sukumar,et al.  Human Telomerase Reverse Transcriptase ( hTERT ) Gene Expression in Thyroid Neoplasms 1 , 1999 .

[110]  D. Powell,et al.  The RET/PTC3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids. , 1998, Cancer research.

[111]  T. Ishikawa,et al.  Telomerase activity in thyroid tumors. , 1998, Oncology reports.

[112]  P. De Giuli,et al.  Galectin-3 is a presurgical marker of human thyroid carcinoma. , 1998, Cancer research.

[113]  T. Wang,et al.  Telomerase activity in benign and malignant human thyroid tissues. , 1998, British Journal of Cancer.

[114]  S. Sukumar,et al.  Telomerase activity in the differential diagnosis of papillary carcinoma of the thyroid. , 1997, Surgery.

[115]  P. Brousset,et al.  Telomerase activity in human thyroid carcinomas originating from the follicular cells. , 1997, The Journal of clinical endocrinology and metabolism.

[116]  T. Fahey,et al.  Telomerase activity in benign and malignant thyroid diseases. , 1997, Surgery.

[117]  M. Oshimura,et al.  Significant Correlation of Telomerase Activity in Thyroid Papillary Carcinomas with Cell Differentiation, Proliferation and Extrathyroidal Extension , 1997, Japanese journal of cancer research : Gann.

[118]  T. Seyama,et al.  Continued expression of a tissue specific activated oncogene in the early steps of radiation-induced human thyroid carcinogenesis , 1997, Oncogene.

[119]  M. Sack,et al.  HBME-1 immunostaining in thyroid fine-needle aspirations: a useful marker in the diagnosis of carcinoma. , 1997, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[120]  S. Sukumar,et al.  Telomerase activity: a marker to distinguish follicular thyroid adenoma from carcinoma. , 1997, Cancer research.

[121]  K. Shroyer,et al.  Telomerase activity in benign and malignant thyroid tumors. , 1997, Thyroid : official journal of the American Thyroid Association.

[122]  Y. Nikiforov,et al.  Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. , 1997, Cancer research.

[123]  L. Crapo,et al.  The epidemiology of thyroid disease and implications for screening. , 1997, Endocrinology and metabolism clinics of North America.

[124]  E. Campo,et al.  GALECTIN‐3 AND LAMININ EXPRESSION IN NEOPLASTIC AND NON‐NEOPLASTIC THYROID TISSUE , 1997, The Journal of pathology.

[125]  G. Chiappetta,et al.  Development of thyroid papillary carcinomas secondary to tissue-specific expression of the RET/PTC1 oncogene in transgenic mice. , 1996, Oncogene.

[126]  R. Lotan,et al.  Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications. , 1995, The American journal of pathology.

[127]  T. Seyama,et al.  In vitro irradiation is able to cause RET oncogene rearrangement. , 1993, Cancer research.

[128]  E. Mazzaferri,et al.  Management of a solitary thyroid nodule. , 1993, The New England journal of medicine.

[129]  H. Gharib,et al.  Fine-Needle Aspiration Biopsy of the Thyroid: An Appraisal , 1993, Annals of Internal Medicine.

[130]  T. Tahira,et al.  Detection of the PTC/retTPC oncogene in human thyroid cancers. , 1992, Oncogene.

[131]  I D Hay,et al.  Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. , 1992, The Journal of clinical investigation.

[132]  L. Weiss,et al.  Immunopathologic and molecular studies as an aid to the diagnosis of malignant mesothelioma. , 1992, Human pathology.

[133]  H. Conte,et al.  Critical Appraisal of the Evidence , 1986, Annals of the New York Academy of Sciences.

[134]  E. A. Gaston,et al.  The significance of nontoxic thyroid nodules. Final report of a 15-year study of the incidence of thyroid malignancy. , 1968, Annals of internal medicine.

[135]  R. Seethala.  MicroRNA deregulation in human thyroid papillary carcinomas , 2008 .

[136]  Amy Y. M. Au,et al.  PAX8-peroxisome proliferator-activated receptor gamma (PPARgamma) disrupts normal PAX8 or PPARgamma transcriptional function and stimulates follicular thyroid cell growth. , 2006, Endocrinology.

[137]  T. Fahey.  Genetic Classification of Benign and Malignant Thyroid Follicular Neoplasia Based on a Three-Gene Combination , 2006 .

[138]  Amy Y. M. Au,et al.  PAX8-Peroxisome Proliferator-Activated Receptor γ (PPARγ) Disrupts Normal PAX8 or PPARγ Transcriptional Function and Stimulates Follicular Thyroid Cell Growth , 2006 .

[139]  A. Miyauchi,et al.  Telomerase activity in thyroid neoplasms evaluated by the expression of human telomerase reverse transcriptase (hTERT). , 2005, Anticancer research.

[140]  Gabriel A. Rabinovich,et al.  Galectins as modulators of tumour progression , 2005, Nature Reviews Cancer.

[141]  N. Eberhardt,et al.  PPARgamma staining as a surrogate for PAX8/PPARgamma fusion oncogene expression in follicular neoplasms: clinicopathological correlation and histopathological diagnostic value. , 2005, The Journal of clinical endocrinology and metabolism.

[142]  S. Ishii,et al.  A multi-class predictor based on a probabilistic model: application to gene expression profiling-based diagnosis of thyroid tumors , 2005, BMC Genomics.

[143]  N. Eberhardt,et al.  The PAX8/PPARgamma fusion oncoprotein transforms immortalized human thyrocytes through a mechanism probably involving wild-type PPARgamma inhibition. , 2004, Oncogene.

[144]  A. Gill,et al.  Detection of the PAX8-PPAR gamma fusion oncogene in both follicular thyroid carcinomas and adenomas. , 2003, The Journal of clinical endocrinology and metabolism.

[145]  A. Gamboa-Domínguez,et al.  Telomerase activity in well-differentiated papillary thyroid carcinoma corrrelates with advanced clinical stage of the disease , 2003, Endocrine pathology.

[146]  A. Gill,et al.  Detection of the PAX8-PPARγ Fusion Oncogene in Both Follicular Thyroid Carcinomas and Adenomas , 2003 .

[147]  L. Sobrinho,et al.  Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas. , 2002, The Journal of clinical endocrinology and metabolism.

[148]  J. Sagartz,et al.  Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas. , 1996, Endocrinology.

[149]  A. Kovatich,et al.  Immunohistochemical staining for proliferating cell nuclear antigen, BCL2, and Ki-67 in vulvar tissues. , 1996, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.